Stephens & Co. Maintains Equal-Weight on Myriad Genetics, Raises Price Target to $6

Benzinga · 3d ago
Stephens & Co. analyst Mason Carrico maintains Myriad Genetics (NASDAQ:MYGN) with a Equal-Weight and raises the price target from $3 to $6.